Telix’s Pixclara approval reinforces the expanding role of targeted PET tracers in neuro-oncology. With Pixclara, the FDA approved the first FET-PET imaging agent for glioma and the first U.S.-approved PET radiopharmaceutical specifically targeting brain cancer. The approval comes nearly 18 months after a complete response letter requested additional clinical evidence, reflecting the regulatory bar for imaging agents where clinical utility depends on differentiation accuracy between recurrent glioma and treatment-related changes. Clinically, a more specific imaging workflow can reduce uncertainty in disease course assessment, affecting decisions on reoperation, systemic therapy sequencing, and clinical trial enrollment. For imaging developers and companion diagnostic teams, the approval sets another precedent for how the agency evaluates evidence packages for radiopharmaceuticals tied to neurologic indications.